Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

C4 Therapeutics (CCCC) EBT (2019 - 2026)

C4 Therapeutics has reported EBT over the past 8 years, most recently at -$25.1 million for Q1 2026.

  • For Q1 2026, EBT rose 4.53% year-over-year to -$25.1 million; the TTM value through Mar 2026 reached -$103.7 million, down 0.52%, while the annual FY2025 figure was -$104.9 million, 0.3% changed from the prior year.
  • EBT for Q1 2026 was -$25.1 million at C4 Therapeutics, down from -$20.4 million in the prior quarter.
  • Over five years, EBT peaked at -$17.7 million in Q2 2024 and troughed at -$37.2 million in Q4 2022.
  • A 5-year average of -$29.1 million and a median of -$28.4 million in 2024 define the central range for EBT.
  • Biggest five-year swings in EBT: crashed 137.48% in 2022 and later soared 50.68% in 2024.
  • Year by year, EBT stood at -$37.2 million in 2022, then increased by 7.28% to -$34.5 million in 2023, then grew by 0.1% to -$34.4 million in 2024, then skyrocketed by 40.87% to -$20.4 million in 2025, then decreased by 23.39% to -$25.1 million in 2026.
  • Business Quant data shows EBT for CCCC at -$25.1 million in Q1 2026, -$20.4 million in Q4 2025, and -$32.2 million in Q3 2025.